Immunocore Holdings (IMCR) Revenue (2023 - 2026)

Immunocore Holdings has disclosed Revenue across 4 years of filings, most recently posting $106.7 million for Q1 2026.

• Revenue for Q1 2026 came in at $106.7 million, up 13.63% year-over-year; the trailing twelve-month figure through Mar 2026 was $412.8 million (up 23.75% YoY), and the FY2025 annual result was $400.0 million, up 28.95% from the prior year.
• Revenue came in at $106.7 million for Q1 2026 at Immunocore Holdings, up from $104.5 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $106.7 million in Q1 2026 to a low of $54.7 million in Q1 2023.
• The 4-year median for Revenue is $80.2 million (2024), against an average of $82.0 million.
• Across the five-year window, Revenue soared 33.16% in 2025 and rose 13.63% in 2026, its largest moves.
• Immunocore Holdings' Revenue stood at $70.2 million in 2023, then rose by 19.8% to $84.1 million in 2024, then advanced by 24.3% to $104.5 million in 2025, then gained by 2.1% to $106.7 million in 2026.
• The last three Revenue figures came in at $106.7 million (Q1 2026), $104.5 million (Q4 2025), and $103.7 million (Q3 2025), per Business Quant data.